The GLP is committed to full transparency. Download and review our 2019 Annual Report

Petition to lift 23andMe FDA ban reaches 10k signatures

| | January 23, 2014

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Back in November, the Food and Drug Administration sent a letter to the genotype-screening company, 23andMe, basically ordering it to stop offering its $99 direct-to-consumer Personal Genome Service to the public. In December, the company knuckled under the regulators’ demands.

The TechFreedom think tank launched a petition with the goal of urging FDA regulators to back off.

The TechFreedom petition has now garnered 10,000 signatures.

n a media statement, TechFreedom president Berin Szoka said:

As our petition shows, thousands of Americans were appalled when the FDA ordered 23andMe to stop marketing its home genetics testing kits. The agency claims such tests will cause users to get too little, or too much, treatment. But the FDA hasn’t offered any real evidence that Americans are so foolish about their own health.

Read the full, original story: Petition In Support of Lifting the FDA Ban on 23andMe Gene Testing Reaches 10,000

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend